Celldex Therapeutics
Logotype for Celldex Therapeutics Inc

Celldex Therapeutics (CLDX) investor relations material

Celldex Therapeutics Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Celldex Therapeutics Inc
Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary11 Feb, 2026

Key milestones and clinical development

  • Initiated two phase 3 studies in cold urticaria and symptomatic dermographism in December 2025, each with 120 patients, targeting 18-month timelines.

  • Ongoing two large phase 3 CSU studies across 500+ centers in 43 countries, aiming for 1,830 patients and enrollment completion by summer 2026.

  • Phase 2 studies in prurigo nodularis and atopic dermatitis completed; data readouts expected in the second half of 2026, with phase 3 studies to follow based on results.

  • Exploring additional indications such as food allergy, allergic rhinitis, and chronic pruritic itch, with potential development starting late 2026 or 2027.

  • Bispecific antibody CDX-622 in healthy volunteer studies, with multiple ascending dose and subcutaneous data expected in summer; proof-of-mechanism asthma study initiated.

Clinical data and physician feedback

  • Phase 2 CSU data show rapid and high complete response rates (up to 70%) and durable effects, with 41% maintaining response seven months post-treatment.

  • Quality of life and angioedema improvements reported, generating strong enthusiasm among investigators.

  • Long-term durability data presented at major conferences, with ongoing discussions about changing treatment paradigms.

  • Retreatment in CIndU study demonstrated successful efficacy upon symptom recurrence.

Safety and study design

  • Safety profile remains consistent and well-tolerated, with mild, reversible side effects related to KIT inhibition.

  • Phase 3 CSU studies closely mirror phase 2 design, with the addition of a loading dose; primary endpoint at 12 weeks, but full analysis after 24 weeks.

  • Large safety database being built with over 1,800 patients in CSU studies, supporting regulatory requirements.

Commercial differentiation for Barzolvolimab
CDX-622: How to prioritize future indications
CSU Phase 3 data readout timing?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Celldex Therapeutics earnings date

Logotype for Celldex Therapeutics Inc
Q4 202523 Feb, 2026
Celldex Therapeutics
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Celldex Therapeutics earnings date

Logotype for Celldex Therapeutics Inc
Q4 202523 Feb, 2026

The essential earnings season companion

The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Celldex Therapeutics, Inc. is a biopharmaceutical company specializing in the development of therapeutic monoclonal and bispecific antibodies. These antibodies are designed to treat a range of serious conditions, including inflammatory, allergic, and autoimmune diseases. The company's lead program focuses on developing barzolvolimab, a monoclonal antibody targeting KIT, a key receptor tyrosine kinase involved in mast cell function, which is crucial in the onset and progression of various severe diseases. Celldex Therapeutics is headquartered in Hampton, New Jersey, and its shares are listed on the NASDAQ.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage